In keeping with this, the combination of a BCL-XL inhibitor (A-1331852) with an AKT (ipatasertib) or pan-PI3K inhibitor (buparlisib) was synergistic in PTEN deficient PC3 and LNCaP prostate cancer cell lines [230]. Here, AKT1 is linked to prostate carcinoma.